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Abstract
Background: Clostridium difficile is the most common infectious etiology of nosocomial diarrhea. Fecal calprotectin
(fc) is a sensitive marker of intestinal inflammation, found to be associated with enteric bacterial infections and
inflammatory bowel disease.
Methods: We evaluated fc levels using a Chemiluminescent immunoassay method, in hospitalized patients with
C. difficile infection (CDI) diagnosed by molecular stool examination and assessed correlation with virulent ribotype 027
strain infection, antibiotic susceptibility by gradient Etest strip performed on C. difficile colonies and clinical and laboratory
measures of disease severity. Statistical analysis was performed for correlation of fc levels with clinical and laboratory
parameters, disease severity and patient outcomes.
Results: Overall 29 patients with CDI were admitted at the Poria medical center in northern Israel, during June 2014-May
2015. Resistance to metronidazole was found in 3 (10.3 %) isolates and to vancomycin in 5 (17.2 %) isolates. Regarding
patient outcomes, within 30 days of CDI diagnosis, recurrence of disease occurred in 10 (34.5 %) patients and 2 patients
(6.9 %) died. Seven (24.1 %) isolates were C. difficile ribotype 027. Mean fc level was 331.4 μg/g (21–932). Higher fc levels
were found in patients with C. difficile ribotype 027 (p < 0.0005). Fc levels were also correlated with elevated peripheral
blood white cell count (p = 0.0007). A trend for higher fc levels was found in patients with a higher clostridium severity
score index (p = 0.0633). No correlation was found between fecal calprotectin levels and age, sex, functional status,
community versus hospital acquired CDI, antibiotic susceptibility, fever, and creatinine levels.
Conclusions: Our study highlights the fact that fc has a potential role as a biomarker of disease severity and binary
toxin producing ribotype associated disease.
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Background
Clostridium difficile (C. difficile) is the most common in-
fectious etiology of nosocomial diarrhea in acute care
settings, accounting for 15–25 % of all cases of antibiotic-
induced diarrhea. C. difficile infection (CDI) is caused by
toxigenic C. difficile that usually produces 2 major
toxins – toxin A, an enterotoxin, and toxin B, a potent
cytotoxin [1–3]. The emergence of a hyper-virulent clone
of C. difficile, ribotype 027, in North America and Europe
in the 2000s has caused numerous outbreaks in the
healthcare setting [4]. Most patients develop diarrhea
during or shortly after starting antibiotics. However,
25–40 % of patients may not become symptomatic for
as long as 10 weeks after completing antibiotic therapy.
Symptoms range from mild watery diarrhea and cramping
abdominal pain, to fulminant colonic infection with com-
plications of toxic megacolon, perforation and death.
Several scoring systems that predict disease prognosis and
aid in treatment decisions have been developed, including
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the clostridium severity score index that incorporates 9
clinical and laboratory variables. Antibiotic treatment of
CDI consists of metronidazole in mild cases and vanco-
mycin in moderate to severe infection, although treatment
failures and recurrence of disease occur often [5, 6]. Fecal
calprotectin (fc) is a sensitive marker of intestinal inflam-
mation, and was found to be associated with enteric
bacterial infections and inflammatory bowel disease [7].
Calprotectin is a 24 kDa dimer of calcium binding pro-
teins S100A8 and S100A9. The complex accounts for up
to 60 % of the soluble protein content of the neutrophil
cytosol. In vitro studies show that calprotectin has bac-
teriostatic and fungistatic properties that arise from its
ability to sequester manganese and zinc [8, 9].
The aim of our study was to evaluate fc levels in hos-
pitalized patients with CDI and to assess if fc levels are
correlated with ribotype 027 strain infection, with reduced
susceptibility of the infectious strain to metronidazole or
vancomycin, with clinical and laboratory tools of disease se-
verity, as calculated by the Clostridium severity score index.
Results
Out of 29 patients with CDI, 15 were females and 14
were males. Mean age was 64.5 years (17–95). Fifteen pa-
tients (51.7 %) were functionally debilitated and 5 (17.2 %)
were nursing home residents. Thirteen patients (44.8 %)
were community acquired cases and 16 patients (55.2 %)
represented nosocomial CDI. In 24 cases the Clostridium
severity score index was ≤3, and a score of 4–6 points was
calculated in 5 patients. Reduced susceptibility to metro-
nidazole was found in 3 (10.3 %) isolates and to vanco-
mycin in 5 (17.2 %) isolates. Regarding patient outcomes,
within 30 days of CDI diagnosis, recurrence of disease
occurred in 10 (34.5 %) patients, and 2 patients (6.9 %)
had died. One patient (3.4 %) developed a toxic megaco-
lon. Seven (24.1 %) isolates were identified as C. difficile
ribotype 027. Among the 13 community acquired patients
with CDI, only 2 had the 027 ribotype, and among the 16
nosocomial cases, 5 were 027 ribotype positive. The mean
severity score for ribotype 027 patients was 2.86 versus
1.95 in ribotype 027 negative patients.
Mean calprotectin level was 331.4 μg/g (21–932). We
performed assessment of the correlation between fecal cal-
protectin levels and clinical and laboratory parameters. We
found higher calprotectin levels in patients with C. difficile
ribotype 027, with a mean level of 811.9 μg/g (659–932),
compared to patients with other C. difficile ribotypes, with
a mean level of 178.6 μg/g (21–522), p < 0.0005 (Fig. 1). A
significantly positive correlation of calprotectin levels was
found with elevated peripheral blood white cell count
(p = 0.0007). A trend for higher calprotectin levels was
found in patients with a higher clostridium severity score
index (p = 0.0633). No correlation was found between fecal
calprotectin levels and age, sex, functional status, commu-
nity versus nosocomial acquired CDI, antibiotic suscepti-
bility, fever, and creatinine levels (Table 1). No correlation
was found between fc levels and disease recurrence or
mortality at 30 days, with a mean level of 284.7 μg/g
(46–840) versus 356.1 μg/g (21–932) in those with and
without recurrence, and 579.5 μg/g (248–911) versus
313.1 μg/g (21–932) in the patients who died versus those
that survived (p = 0. 6662 and p = 0.255, respectively.).
Discussion
C. difficile is the leading infectious cause of antibiotic-
associated diarrhea. CDI symptoms range from mild watery
Fig. 1 Fecal Calprotectin levels in patients with Clostridium difficile infection. and correlation with fecal Calprotectin levels
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diarrhea to severe colitis, toxic megacolon, colonic perfor-
ation, and death. Guidelines for treatment of CDI stratify
antibiotic treatment according to disease severity [6].
Currently there are several scoring systems, these con-
sist of non-specific clinical and laboratory parameters
that, as a whole, estimate disease severity and patient
prognosis [10–12]. The search for specific markers in-
dicative of disease severity is of great importance. As an
example, in one study it was found that elevated PCT
levels are associated with the severe CDI [13].
Recently, a few studies found that fecal calprotectin
levels are associated with acute bacterial gastroenteritis
[14, 15], despite the fact that up to now fc was used only
to stratify between inflammatory and non-inflammatory
bowel diseases. Calprotectin is a 24 kDa dimer of cal-
cium binding proteins that accounts for up to 60 % of
the soluble protein content of the neutrophil cytosol.
Several recent studies found that fc levels are elevated in
patients with CDI, compared with patients with non-C.
difficile antibiotic-associated diarrhea and with patients
with C. difficile colonization only [16,17]. In this study
we aimed to find if fc levels are correlated with CDI
severity and with disease caused by ribotype 027; this
specific strain is associated with higher morbidity and
mortality rates and increased antibiotic resistance. We
found that fc levels were significantly associated with C.
difficile ribotype 027. In routine practice most microbiol-
ogy laboratories do not regularly assess C. difficile ribo-
type because the diagnosis is based on ELISA toxin
assays, which don’t identify ribotypes. However, the ele-
vated fc levels might alert clinicians to the possibility of
a more severe and complicated course of disease that is
associated with this ribotype. This may also affect em-
piric choice of the antibiotic therapy. For example, fidax-
omicin treatment decreases recurrence rates in CDI, but
not in cases of ribotype 027 associated disease [18]. An-
other study of 164 patients with CDI found a non-
significant correlation of fc levels and ribotype 027 [16].





P -value for correlation
with fc levels
Antibiotic-reduced susceptibility
Metronidazole 3 (10.3 %) Reduced susceptibility to Metronidazole:
177.7 (46–287)
0.5474
Metronidazole susceptible 349 (21–932)
Vancomycin 5 (17.2 %) Reduced susceptibility to Vancomycin
336.8 (113–932)
0.7316
Vancomycin susceptible 330.3 (21–912)
Gender
Male 15 (51.7 %) 340.8 (48–932)
Female 14 (48.3 %) 321.4 (21–911) 0.7622
Age (years) 64.5 (17–95) 0.2764
Functional status
Independent 14 (48.3 %) 316.8 (21–932)
Debilitated 15 (51.7 %) 45.1 (46–911) 0.6815
CDI acquisition
Community 10 (34.5 %) 273.6 (21–911)
Nursing home 3 (10.3 %) 234.7 (21–411)
Hospital 16 (55.2 %) 385.8 (46–932) 0.5678
Body temperature (°C) 37.0 (36–39.4) 0.8772
Peripheral white blood cell count (/μl) 13,363 (3070–43,210) 0.0007
Creatinine(g/dL) 1.3 (0.2–6.7) 0.2
Disease recurrence in 30 days 10 (34.5 %) Disease recurrence 284.7 (46–800) 0.6662
No recurrence 356.1 (21–932)
30 day mortality
Yes 2 (6.9 %) 579.5 (248–911)
No 27 (93.1 %) 313.3 (21–932) 0.2550
Clostridium severity score index 2.17 (1–6) 0.0633
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This might be due to analysis of fc levels in 4-tier per-
centile categories and not as a linear value as done in
our study. We also found fc levels to be significantly as-
sociated with a higher peripheral blood white cell count,
which might reflect an elevated degree of intestinal in-
flammation that is associated with fc stool levels. In this
study there was a trend towards higher fc levels in patients
with more severe disease as assessed by the clostridium
severity score index. Statistical significance may not have
been achieved due to the relatively small sample size. One
other study assessed the correlation between disease se-
verity and fc levels and found a non-significant higher
mean stool fc level in patients with severe disease, al-
though in this study a different severity scoring system
was used [16].
The main limitation of our study was the small sample
size, reflecting the fact that our medical center is a 300
bed hospital serving only the North-East of Israel and
thus we do not have many patients with community ac-
quired CDI, and due to rigorous infection control pro-
grams we do not have many cases of nosocomial CDI as
well. The patients in this paper represent all patients
with CDI at our hospital during one year. A larger sam-
ple size might have helped us find a stronger correlation
between fc levels and disease severity and outcomes.
Conclusions
Finding novel and easy performance tools for the assess-
ment of CDI severity is an important and crucial goal.
Our study highlights the fact that fc has a potential role




Overall, 29 patients with diarrhea, who were found posi-
tive for C. difficile from June 2014 to May 2015, were ad-
mitted at the Poria Medical Center located in northern
Israel. Identification of C. difficile from patients’ stool
specimens was carried out on a bio-molecular platform,
which also enables identification of C. difficile ribotype
027 (Xpert® C. difficile, Cepheid, Sweden) [19]. The follow-
ing demographic and clinical data concerning patients
with CDI were collected from electronic files: age, sex,
functional status, community versus nosocomial acquired
CDI, and antibiotic susceptibility.
A clostridium severity score index was calculated. For
each patient the score incorporated nine parameters, each
variable added one point: altered mental status, abdominal
pain or distention, 1500 >WBC > 20,000, ALB < 2.5, as-
cites or colitis (imaging), MAP < 65, pulse > 110, ICU
transfer. A score of 0–3 criteria meant mild disease, 4–6:
moderate disease, ≥7: severe disease [10].
The study protocol was reviewed and approved by the
Poria-Baruch Padeh Medical Centre Institutional Review
Board/Ethics Committee. A waiver was ushered for in-
formed patient consent.
Fecal calprotectin test
Calprotectin levels in stool were examined by Liaison®
Calprotectin Stool (Saluggia, Italy) kit using Chemilu-
minescent immunoassay (CLIA).
Bacterial culture and determination of in vitro
susceptibility
Antibiotic susceptibility test was performed by culture
method of the stool sample on chromID™ C. difficile
(bioMérieux, Durham, NC) growth medium and then in-
cubated at 37 °C in anaerobic conditions for 18–12 h. C.
difficile colonies appear as asymmetric and black-colored
colonies [20]. One isolated C. difficile colony from the
culture was suspended in Thioglycollate broth (Becton
Dickinson, Heidelberg, Germany (until density of 1.0
McFarland was reached. The inoculum was spread by
cotton swab on Brucella Blood Agar growth medium,
supplemented with haemin and vitamin K (Becton Dick-
inson, Heidelberg, Germany (. MIC determination for
metronidazole and vancomycin was performed by a gra-
dient Etest strip (bioMérieux, Durham, NC). Further,
antibiotic susceptibility plates were incubated in anaer-
obic conditions at 37 °C for 24 h. The interpretation of
susceptibility test results was performed in accordance
with European Committee on Antimicrobial Susceptibility
Testing (EUCAST) recommendations. Based on these
recommendations, C. difficile isolates are considered as
strains with reduced susceptibility values to metronida-
zole or vancomycin when MIC level >2 mg/L [21].
Statistical analysis
Chi-square test was applied for analyzing the differences
in categorical parameters by NAP-1. The Non-parametric
Wilcoxon-Mann–Whitney Rank sum was applied for ana-
lyzing the difference in the quantitative parameters by
NAP-1, and for analyzing differences in calprotectin levels
between categorical variables (recurrence, reduced anti-
biotic susceptibility, death, gender, nursing house, func-
tion, and confusion). Pearson correlation was used for
testing the association between calprotectin and quantita-
tive parameters for testing the association between calpro-
tectin and categorical parameters. Analysis of Covariance
(ANCOVA) model was applied for analyzing the different
calprotectin levels by NAP-1 with adjustment to confu-
sion, index-1, and age. All tests applied were two-tailed,
and a p value of 5 % or less was considered statistically sig-
nificant. The data was analyzed using SAS® version 9.3
(SAS Institute, Cary, North Carolina).
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